구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dimerizer drug AP1903 (Dimerizer drug AP1903) Centre Hospitalier Universitaire d…·Graft Versus Host Disease 6 trials |
|---|---|
Overview Program | Dimerizer drug AP1903 |
Overview Company | Centre Hospitalier Universitaire de Besancon |
Overview Modality | CGT |
Overview Target | Graft Versus Host Disease |
Overview Indication | Graft Versus Host Disease; Hematological Malignancies |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Safety signal | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dimerizer drug AP1903 (Dimerizer drug AP1903) Centre Hospitalier Universitaire d…·Graft Versus Host Disease 6 trials |
|---|---|
Overview Program | Dimerizer drug AP1903 |
Overview Company | Centre Hospitalier Universitaire de Besancon |
Overview Modality | CGT |
Overview Target | Graft Versus Host Disease |
Overview Indication | Graft Versus Host Disease; Hematological Malignancies |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Safety signal | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교